How much revenue does Chongqing Genrix Biopharmaceutical make?

Chongqing Genrix Biopharmaceutical reported 30.09 million CNY in revenue for fiscal year 2024, up 2384.1% from 1.21 million CNY in fiscal year 2023. In Q2 2025 revenue was 25.24 million CNY.

What companies are similar to Chongqing Genrix Biopharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ), Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ), Pacific Shuanglin Bio-pharmacy Co., Ltd. (000403.SZ), Wanbangde Pharmaceutical Holding Group Co., Ltd. (002082.SZ).

Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SS) Stock

About Chongqing Genrix Biopharmaceutical Co., Ltd.

Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondyloarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic ...

At a glance

Chongqing Genrix Biopharmaceutical reported revenue of 30.09 million CNY for fiscal year 2024, up 2384.1% from fiscal year 2023, and net income of -797.27 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 25.24 million CNY, up 398572.5% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.